Inactive Instrument

Medivation Inc Stock

Stocks

End-of-day quote Nasdaq Other stock markets
- ^USD	-

28/10/16	Eli Lilly and : Drugmaker Sanofi hungry for deals after earnings beat	RE
08/09/16	Exclusive - GW Pharmaceuticals hires investment bank following approaches: sources	RE

28/10/16	Eli Lilly and : Drugmaker Sanofi hungry for deals after earnings beat	RE
08/09/16	Exclusive - GW Pharmaceuticals hires investment bank following approaches: sources	RE
09/07/16	Abbott Laboratories : Medtech's 2016 stock surge confronts second-quarter test	RE
04/06/16	Medivation : Ex-Oppenheimer adviser arrested for trading on Pfizer employee's tips	RE
02/06/16	Medivation : sets eligibility date for shareholder consent on board revamp	RE
26/05/16	Lonza : Sanofi moves to oust Medivation board in $9.3 billion takeover fight	RE
26/05/16	Lonza : Sanofi moves to oust Medivation board in $9.3 billion takeover fight	RE
25/05/16	Exclusive: Sanofi to unveil challenge to Medivation's board - sources	RE
11/05/16	Astellas Pharma : Medivation succumbs to pressure to explore sale - sources	RE
10/05/16	Exclusive - Medivation succumbs to pressure to explore sale: sources	RE
06/05/16	Medivation : Sanofi ready to up offer for drugmaker Medivation, could oust board	RE
05/05/16	Medivation : Sanofi sees 'strong strategic' fit with U.S. Medivation	RE
04/05/16	Exclusive: Pfizer approaches Medivation about potential takeover - sources	RE

09/10/16	Medivation : New Data Presented at ESMO 2016 Further Demonstrates XTANDITM▼ (enzalutamide) Significantly Improves Time to PSA Progression in Advanced Prostate Cancer, Compared with Placebo	BU
10/09/16	Faruqi & Faruqi, LLP : Announces Filing of a Class Action Lawsuit Against Medivation, Inc.	PR
07/09/16	MEDIVATION SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Medivation, Inc. (MDVN) Over the Proposed Sale of the Company to Pfizer Inc.	PR
26/08/16	Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information	BU
26/08/16	Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. for $81.50 Per Share is Fair to Shareholders	BU

28/10/16	Sanofi : relève ses prévisions pour 2016 et s'envole en Bourse
28/10/16	Sanofi : relève ses prévisions pour 2016 et veut céder ses activités génériques en Europe
10/10/16	Medivation : Neue, im Rahmen der ESMO 2016 präsentierte Ergebnisse belegen zusätzlich, dass XTANDITM▼ (Enzalutamid) die Zeit bis zur PSA-Progression bei fortgeschrittenem Prostatakarzinom im Vergleich zu Placebo signifikant verlängert
10/10/16	Medivation : De nouvelles données présentées au Congrès 2016 de l’ESMO démontrent une fois de plus que XTANDITM▼ (enzalutamide) améliore nettement, par rapport au placebo, le délai avant progression du PSA en cas de cancer de la prostate avancé
19/09/16	Sanofi : poursuit Merck en justice aux USA pour protéger les brevets de Lantus

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+1.03%	+7.52%	+54.74%	+114.98%	55.58B
WUXI APPTEC CO., LTD.	+2.72%	+3.06%	+53.28%	+47.85%	43.47B
BIONTECH SE	+1.22%	+2.68%	-13.80%	-17.62%	22.64B
INSMED INCORPORATED	+1.71%	+4.40%	+1.54%	+404.46%	20.96B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-4.13%	+16.62%	-30.70%	15.79B
GENMAB A/S	+0.15%	+0.50%	+9.10%	-40.04%	15.3B
EXELIXIS, INC.	-0.62%	+0.83%	+27.19%	+178.37%	13.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+6.41%	+21.05%	-	11.74B
PHARMAESSENTIA CORPORATION	+1.61%	+1.17%	+90.79%	+212.97%	10.96B
Average	+1.85%	+0.26%	+28.94%	+108.78%	23.32B
Weighted average by Cap.	+1.75%	+1.60%	+33.77%	+101.87%